Novel spiroaminodihydropyrroles probing for optimized interactions at the P3 pocket of β-secretase 1 (BACE1) were designed with the use of free energy perturbation (FEP) calculations. The resulting molecules showed pIC50 potencies in enzymatic BACE1 inhibition assays ranging from approximately 5 to 7. Good correlation was observed between the predicted activity from the FEP calculations and experimental activity. Simulations run with a default 5 ns approach delivered a mean unsigned error (MUE) between prediction and experiment of 0.58 and 0.91 kcal/mol for retrospective and prospective applications, respectively. With longer simulations of 10 and 20 ns, the MUE was in both cases 0.57 kcal/mol for the retrospective application, and 0.69 and 0.59 kcal/mol for the prospective application. Other considerations that impact the quality of the calculations are discussed. This work provides an example of the value of FEP as a computational tool for drug discovery.

A series of acylguanidine beta secretase 1 (BACE1) inhibitors with modified scaffold and P3 pocket substituent was synthesized and studied with free energy perturbation (FEP) calculations. The resulting molecules showed potencies in enzymatic BACE1 inhibition assays up to 1 nM. The correlation between the predicted activity from the FEP calculations and the experimental activity was good for the P3 pocket substituents. The average mean unsigned error (MUE) between prediction and experiment was 0.68 ± 0.17 kcal/mol for the default 5 ns lambda window simulation time improving to 0.35 ± 0.13 kcal/mol for 40 ns. FEP calculations for the P2' pocket substituents on the same acylguanidine scaffold also showed good agreement with experiment and the results remained stable with repeated simulations and increased simulation time. It proved more difficult to use FEP calculations to study the scaffold modification from increasing 5 to 6 and 7 membered-rings. Although prediction and experiment were in agreement for short 2 ns simulations, as the simulation time increased the results diverged. This was improved by the use of a newly developed "Core Hopping FEP+" approach, which also showed improved stability in repeat calculations. The origins of these differences along with the value of repeat and longer simulation times are discussed. This work provides a further example of the use of FEP as a computational tool for molecular design.

The first direct α-arylation of aldehyde-derived N,N-dialkylhydrazones with electron deficient aryl and heteroaryl cyanides under visible-light photoredox catalysis has been developed. Structurally complex α,α'-diaryl-N,N-cycloalkylhydrazones were obtained in moderate yields by repetition of the direct arylation protocol. A continuous-flow procedure for the preparation of α-aryl-N,N-dialkylhydrazones on a multigram scale has also been established.

The synthesis of new fluorinated pyrrolidones starting from unprotected amino esters and amino nitriles through a Michael addition-lactamization sequence is described. The resulting CF3 -containing building blocks, bearing a quaternary stereogenic center adjacent to the fluorinated group, have been converted into amino pyrrolidines that display potent β-secretase 1 (BACE1) inhibitory activity. This work constitutes an example of selective fluorination as a valid strategy for the modulation of physicochemical and biological properties of lead compounds in drug discovery.

The groups of Santos Fustero at the University of Valencia (Spain) and Oscar Delgado at Janssen Research and Development (Spain) have been invited for the front cover of this issue. The image depicts the docking of one of the β‐secretase 1 (BACE1) inhibitors encapsulated in a sketch of the human brain. Read the full text of the article at .

The synthesis of new fluorinated pyrrolidones (III) starting from unprotected amino esters and amino nitriles (II) through a Michael addition-lactamization sequence is described. The resulting building blocks, bearing a quaternary stereogenic center adjacent to the fluorinated group, are converted into aminopyrrolidines that display potent -secretase inhibitory activity, such as (IV) and (V). -(MATEU, N.; CIORDIA, M.; DELGADO, O.; SANCHEZ-ROSELLO, M.; TRABANCO, A. A.; VAN GOOL, M.; TRESADERN, G.; PEREZ-BENITO, L.; FUSTERO*, S.; Chem. -Eur. J. 21 (2015) 33, 11719-11726, http://dx.

The cover picture shows the docking of one of the β‐secretase 1 (BACE1) inhibitors designed and synthesized in this study in complex with the crystal structure of the enzyme (PDB ID: 3ZOV). This appears encapsulated in a sketch of the human brain, and the molecular structure of the inhibitors is shown in the circle. For the comprehensive study, see the Full Paper by N. Mateu, O. Delgado, S. Fustero, and colleagues on